Trabikibart

Trabikibart (CSL311), a βc (CSF2RB) -specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human βc receptor. Trabikibart has picomolar binding affinity for the human βc receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research[1].

Product Specifications

CAS Number

[2643974-98-3]

Product Name Alternative

CSL311

UNSPSC

12352203

Target

C-Fms

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/trabikibart.html

Purity

99.17

Solubility

10 mM in DMSO

Smiles

[Trabikibart]

Molecular Weight

(144.66 kDa)

References & Citations

[1]Con Panousis, et al. CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors. MAbs. 2016;8 (3) :436-53.